Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453848 | 0.84 | DRD4 (0.66) | ALDH1A1MAPK1DRD4POLBTP53 | |
| SCHEMBL4004690 | 0.82 | MAPK1 (0.67) | ALDH1A1MAPK1MEN1KMT2ATAAR1 | |
| SCHEMBL16900136 | 0.76 | NPSR1 (0.67) | ALDH1A1MEN1KMT2ADRD4TP53 | |
| SCHEMBL4004192 | 0.76 | MAPK1 (0.80) | ALDH1A1MAPK1MEN1KMT2ADRD4 | |
| SCHEMBL15624932 | 0.76 | ALDH1A1 (0.82) | ALDH1A1MAPK1MEN1KMT2ALMNA | |
| SCHEMBL5142574 | 0.75 | POLB (0.76) | ALDH1A1MAPK1MEN1KMT2APOLB | |
| SCHEMBL26628146 | 0.75 | POLB (0.58) | ALDH1A1MEN1KMT2APOLBMAPT | |
| Ammonia Solution, Strong SCHEMBL15558678 | 0.75 | NPSR1 (0.65) | ALDH1A1MEN1KMT2ADRD4TP53 | |
| SCHEMBL6944191 | 0.74 | KDM4E (0.63) | ALDH1A1MEN1KMT2APOLBATM | |
| SCHEMBL13667856 | 0.73 | POLB (0.68) | ALDH1A1MAPK1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | ALDH1A1 4501/4885MAPK1 59/4885MEN1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.